Celgene wins in Federal Circuit appeal affirming invalidity of patent asserted against Thalomid® and Revlimid® brand cancer drugs

Client(s) Celgene Corporation

Jones Day successfully defended Celgene Corporation in a patent infringement case brought in the United States District Court for the District of Delaware by Andrulis Pharmaceuticals Corporation, which alleged that Celgene's THALOMID® and REVLIMID® brand cancer drugs infringed U.S. Patent No. 6,140,346 ("'346 patent"). On appeal, the United States Court of Appeals for the Federal Circuit summarily affirmed the district court's judgment that the asserted '346 patent claim is indefinite.

Andrulis Pharmaceuticals Corp. v. Celgene Corp., Appeal No. 2015-1962 (Fed. Cir.)